Indivior's Strategic Turnaround Gains Traction Post-Q2 2025

Indivior (INDV) reported Q2 2025 revenue of $302 million and adjusted EBITDA of $88 million, largely driven by its flagship SUBLOCADE, which generated $209 million in sales and commands approximately 75% of the long-acting injectable OUD market. This performance led to raised full-year revenue guidance to $1.030B-$1.080B and adjusted EBITDA guidance to $275M-$300M. The company is undergoing a strategic transition, including a primary Nasdaq listing and a new three-phase operational plan aimed at efficiency and cash flow, while recent clinical data supports SUBLOCADE's efficacy in high-fentanyl users. Despite potential headwinds from SUBLOCADE's concentration and ongoing legacy product erosion, Indivior's current valuation at a P/E of 12.64x, a significant discount to its sector, and a robust ~9% free cash flow yield, suggest considerable re-rating potential.

Analysis

Indivior PLC is undergoing a significant operational and strategic transition, which the market appears to be undervaluing despite recent positive developments. The company's Q2 2025 results showed a modest 1% year-over-year revenue increase to $302 million, beating analyst expectations. This growth was driven almost entirely by its flagship opioid use disorder treatment, SUBLOCADE, which generated $209 million in revenue, a 9% year-over-year and 19% sequential increase. SUBLOCADE now commands approximately 75% of the long-acting injectable market, with key engagement metrics like active prescribers growing 14% year-over-year. In a strategic move to align with its revenue base, Indivior has shifted its primary listing to the Nasdaq and gained inclusion in the Russell 2000 and 3000 indices, a move designed to enhance liquidity and attract institutional capital. Management has demonstrated confidence by raising full-year 2025 guidance for revenue to $1.030-$1.080 billion and adjusted EBITDA to $275-$300 million. However, significant headwinds remain, including heavy reliance on SUBLOCADE, anticipated pricing pressure on the legacy SUBOXONE product, and high SG&A costs relative to peers. Furthermore, a 7% discrepancy between SUBLOCADE's reported sales and demand-based revenue suggests temporary wholesaler stocking may have inflated Q2 figures. The new CEO's three-phase "Action Agenda" aims to address inefficiencies and drive cash flow, but carries execution risk. Despite these challenges, the company's valuation appears compelling, with a P/E of 12.64x—a notable discount to the sector average of 20.88x—and a strong free cash flow yield of approximately 9%.

Key Decisions for Investors

• The current valuation at a 12.6x P/E and a robust ~9% free cash flow yield appears disconnected from SUBLOCADE's market dominance and the company's upgraded 2025 guidance, suggesting a potential re-rating opportunity for long-term investors.
• Investors should closely monitor the execution of the new CEO's three-phase 'Action Agenda' for tangible progress on cost efficiencies, as success in resetting the operating model is critical to justifying the long-term investment thesis.
• It is crucial to track SUBLOCADE's demand-based revenue growth, distinct from temporary wholesaler stocking effects, and the pace of SUBOXONE's market share erosion to accurately assess the underlying health of the business transition.
• A key catalyst to watch is the company's ability to increase SUBLOCADE's penetration in the commercial payor channel, where a significant mismatch between patient coverage and prescription volume represents a major untapped growth opportunity.